Company Overview and News

 
Downer wins $286m Millmerran mine management contract

2018-09-05 australianmining.com.au
Downer EDI has been awarded a contract extension for its mining services at the Commodore open cut coal mine in South East Queensland.
DOW OZMLF DNERY DOW OZL

 
Downer EDI, Ltd. ADR 2018 Q4 - Results - Earnings Call Slides

2018-08-16 seekingalpha
The following slide deck was published by Downer EDI, Ltd. ADR in conjunction with their 2018 Q4 earnings call.
DOW DNERY DOW

 
Royal Adelaide Hospital services in doubt after contractor's $93.8m loss

2018-08-16 abc.net.au
The future of catering and cleaning services at the Royal Adelaide Hospital are in question, after revelations the company contracted to run them has lost $93.8 million on the contract.
DOW DNERY DOW

 
Downer wins $120m Cobar Management contract

2018-08-09 australianmining.com.au
Downer EDI has secured a $120 million contract to provide mining services at Cobar Management’s CSA underground copper mine in New South Wales.
DOW DNERY DOW

 
Gold Road Resources completes final cost estimate for the Gruyere Gold Project

2018-07-30 proactiveinvestors.com.au
Gold Road Resources Ltd (ASX:GOR) has received the independent third party review of the definitive estimate for its Gruyere Gold Project, representing an estimate of costs to the end of project commissioning.
DOW ELKMF GFI.WI DNERY GOR DOW GFI GFIOF APA

 
OZ Minerals keeps Carrapateena on track

2018-07-18 australianmining.com.au
OZ Minerals’ development of the Carrapateena copper-gold project in South Australia is taking shape as planned.
DOW OZMLF DNERY AVB DOW OZL

 
Adani CEO’s son claims Carmichael mine funded

2018-07-18 australianmining.com.au
India’s Adani has reportedly completed financing for the Carmichael coal mine and is close to securing funds for the rail component of the project.
DOW DNERY DOW

 
Downer wins long-term maintenance contract

2018-07-16 australianmining.com.au
Chevron has awarded Downer EDI a five-year contract to provide maintenance and support services at its Western Australian operations.
DOW DNERY DOW

5
Receivers probe 13 ex-Hawkins companies, call for creditors issued

2018-05-30 nzherald.co.nz
The receivers of 13 businesses previously part of New Zealand's second-largest construction company Hawkins are calling for creditors and say the directors of the businesses are giving their full support in the process.
DOW DNERY DOW

5
Ex-Hawkins Orange-H placed in receivership by shareholder; owes creditors $30 million

2018-05-11 nzherald.co.nz
Orange-H Group, the McConnell entity set up to run down the residual Hawkins assets after the sale to Downer Group, has been tipped into receivership by its shareholder and creditor just 10 days after being ordered to pay $13.4 million over a leaky school.
DOW DNERY DOW

5
OZ closes Prominent Hill open pit

2018-04-17 australianmining.com.au
OZ Minerals has completed its planned closure of the Prominent Hill open pit in South Australia.
DOW OZMLF DNERY AVB DOW OZL

5
OZ Minerals awards $660m Carrapateena contract to Downer

2018-04-16 australianmining.com.au
Downer EDI will deliver underground mining services at OZ Minerals’ Carrapateena copper-gold project in South Australia after being awarded a $660 million contract at the operation.
DOW OZMLF DNERY DOW OZL

5
New Century awards ‘landmark’ training contract at Century mine

2018-03-28 australianmining.com.au
New Century Resources has awarded what has been described as a landmark contract to the Waanyi ReGen Joint Venture (WRJV) to provide training services for Aboriginal and Torres Strait Islander people local to the Century zinc mine in Queensland.
DOW DNERY DOW NCRE

21
CIMIC joins BHP, Rio on LinkedIn top companies list

2018-03-21 australianmining.com.au
CIMIC Group is the first of several mining and related services companies that have been named in LinkedIn’s 2018 Top Companies list for Australia.
CIM DOW RTPPF RIO RIO DNERY RIO DOW RTNTF LGTHF LGTHY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to NZX:DOW / Downer EDI on message board site Silicon Investor.

Who Wonu0027t Be Down For Breakfast? Who Wonu0027t Be Down For Breakfast? Who Wonu0027t Be Down For Breakfast? Windows 10 Windows 10 Windows 10
Market crash like NOW Market crash like NOW Market crash like NOW Silicon Investor for Windows Phone Silicon Investor for Windows Phone Silicon Investor for Windows Phone
Windows Phone Windows Phone Windows Phone Windows 7 Windows 7 Windows 7
Bgt=Smart Cardu0026 Windows 2000 Bgt=Smart Cardu0026 Windows 2000 Bgt=Smart Cardu0026 Windows 2000 Windows 8 Windows 8 Windows 8
Dow Chemical Co. Dow Chemical Co. Dow Chemical Co. Rolling Averages, Their ins and outs and ups and downs Rolling Averages, Their ins and outs and ups and downs Rolling Averages, Their ins and outs and ups and downs